OVERVIEW
Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

POSTER SESSION
Posters will be displayed in Pavilion 4 of the Lisboa Congress Centre from August 25-27. Each day will have a separate poster session:

- **Friday, August 25, Poster Session A**
- **Saturday, August 26, Poster Session B**
- **Sunday, August 27, Poster Session C**

1. Set Up
8:00AM-9:00AM. All posters must be up by 8:45AM.

2. Hours
Pavilions 4/5 will be open from:
8:00AM - 5:00PM .....Friday and Saturday
8:00AM - 2:00PM .....Sunday

All breaks and lunches, as well as exhibits, will be located in Pavilions 4/5.

3. Discussion Time
Presenters should be at their poster from 12:45-1:45PM.

EuroDURG, the European Drug Utilization Research Group, invites all poster presenters displaying their posters on Saturday, August 26, to participate in the EuroDURG poster walk. EuroDURG will offer presenters the opportunity to present their work and to discuss their results with an audience. Please be present at your poster site between 12:45pm and 1:45pm.

When the poster walk chair and audience stops at your poster, please give a brief 3-minutes presentation and answer questions about your research.

4. Poster Prizes
Each day a group of judges will select the three best posters of the session. The presenters will receive ribbons to display on the posters and an invitation to display their posted for the duration of the ICPE.

5. Take Down
All posters must be taken down by 6:30PM on Friday and Saturday; posters must be taken down by 2:30PM on Sunday.

**NOTE:** ISPE and the Lisboa Congress Centre will not be responsible for any poster that is left up overnight or is lost or damaged.

NUMBERING SYSTEM
Each poster board will be numbered. The poster number is the first number listed for the abstract on the following pages. Presenters should attach their posters to the board number corresponding to the number assigned to their poster in the Final Program. Please note the number may differ from that shown in the preliminary program. The abstract number, for use in locating abstracts in the final program and the special issue of Pharmacoeconomics and Drug Safety, is in brackets [ ] after the title of the abstract.

POSTER SPECIFICATIONS

1. Posters must be designed to fit a space 1 meter WIDE by 2.5 meters HIGH.
2. Suggested poster dimensions: 0.93 meters WIDE (3 feet) by 1.63 meters HIGH (5 feet).
3. The board will be the only support device available. Business cards or small leaflet literature for distribution may be inserted in an envelope and affixed to the board.
4. POSTER ORIENTATION: PORTRAIT.
5. Posters may be attached to the boards using 2-sided Velcro tape. All poster presenters are encouraged to bring their own role of 2-side Velcro tape.
1 Diagnostic Characteristics of CD4 Cell Count Response in Predicting Virologic Response in HIV-Infected Patients Initiating HAART in Botswana [143]
Gregory Bisson, Robert Gross, Tendani Gaolatke, Ian Frank, Caitlin Rollins-Kantrowitz, Scarlett Bellamy, Rachel Weinstein, Diana Dickinson, Harvey Friedman, Howard Moffat, Brian Strom, Ndwapu Ndwapu. (United States)

2 Incidence and Risk Factors for Weight Loss during Dual HIV/Hepatitis C Virus Therapy [144]
V Lo Re III, J Kostman, R Gross, R Reddy, M Putt, I Frank, B Strom. (United States)

3 Antibiotic Use in Italian Hospitals 2002-2004 [145]
Maria Chiara Sihani, Elisabetta Poluzzi, Domenico Motola, Petar Strahninj, Antonio Vargiu, Laura Bersaglia, Alberto Vaccheri, Nicola Montanaro. (Italy)

4 Use of Narrow-Spectrum Prophylactic Antibiotics Might Not Be Considered as a Safe Approach in the Management of Women Hospitalized for Preterm Premature Rupture of Membranes (PPROM) [146]
Carole Franceschini, Elise Maurel, Segolene Charra, Frederic Lirussi, Jean-Bernard Couyon, Paul Sagot, Catherine Deneux-Tharaux, Marc Bardou. (France)

5 Age and Sex Specific Antibacterial Prescribing in Norway [147]
Irene Liteskar, Hege S Blix, Anders Engesland, Marit Ronning. (Norway)

6 High Level, but Not Low Level HIV Breakthrough on Efavirenz-Based Regimens Associated with Poor Adherence [148]
Robert Gross, Warren B Bilker, Jennifer Chapman, James C Coyne, Harvey M Friedman, Brian L Strom. (United States)

7 Influence of the 3rd Generation Cephalosporins Utilization on the Occurrence of ESBL-Positive Klebsiella pneumoniae [149]
Karel Urbanek, Milan Kolar, Yvona Loveckova, Lucie Santava. (Czech Republic)

8 Comparative Study of Antimicrobials Utilization in Intensive Care Units in a Region of Belarus [150]
Maxim N Mily, Mikhail L Pivovar, Sergey A Golubev. (Belarus)

9 Profile of the Adverse Reactions of Anti-Infective Notified to the National Center of Monitoring of Medicines – NCMM in the Year of 2005 [151]
Leandro Alves Maceda da Silva, Alzira Santana Santos, Murilo Freitas Dias, Elaine Alves Faria. (Brazil)

10 Prevalence, User Profiles and Health Correlates of Hormone Therapy among German Women before and after WHI Study [152]
Yang Du, Hildebrand Knopf, Hans-Ulrich W Merckel, Christa Schmidt-Nave, Marianne Braemer-Hauth, Ellen Pabel. (Germany)

11 Cyproterone Acetate + Ethinylestradiol as a Treatment for Women with Acne, Hirsutism – What Is the Risk Profile? [153]
Helen E Seaman, Julia Snowball, Corinne S de Vries. (United Kingdom)

12 Health Outcomes in Women Taking Ethinylestradiol/Drospirenone and Other Oral Contraceptives [154]
Jeanne Louglin, John Seeger, P Mona Eng, C Robin Clifford, Jennifer Cutone, Alexander Walker. (United States)

13 European Active Surveillance Study of Women Taking HRT (EURAS-HRT) [155]
Anita Assmann, Juergen C Dinger, Heinemann AJ Heinemann. (Germany)

14 Descriptive Study of Users of Depo-Medroxyprogesterone Acetate (DMPA) in the MHRA GPRD [156]
D Sanchez Matienzo, L L Lanza, L J McQuay, L Gutierrez, A Arana, S Perez-Gutthann. (Spain)

15 Thromboembolism/Hormone Study – A Molecular Epidemiological Nationwide Case-Control Study on Risk and Susceptibility Factors for Venous Thromboembolism in Women [157]
Annica Bergendal, Helle Kieler, Ingemar Persson. (Sweden)

16 The OSAP Europe Project: Presentation of a European Pharmacoepidemiological Survey of the Misuse or Abuse of Marketed Drugs [158]
Maryse Lapeyre-Mestre, Mireille Gony, Ulf Pedersen, Jacob Jacobsen, Henrik T Sorensen. (United States)

17 Profile of the Adverse Reactions of Drugs That Act in the Nervous System Notified to the National Center of Monitoring of Medicines – NCMM in the Year of 2005 [159]
Alzira Santana Santos, Leandro Alves Maceda da Silva, Murilo Freitas Dias, Elaine Alves Faria. (Brazil)

18 Comparative Safety of Long-Acting Bronchodilators [160]
Michele M Jara, Stephan F Lanes, Charles Wentworth III, Corey May, Steven Kesten. (United States)

19 Morbidity and Mortality among Users of Tiotropium in Denmark [161]
Cynthia de Luise, Stephan F Lanes, Lars Pedersen, Jacob Jacobsen, Henrik T Sorensen. (United States)

20 Asthma Exacerbations and Costs in Children Receiving Leukotriene Receptor Antagonists Versus Other Asthma Controllers [162]
Miri Ami Striker, Cinco Picelli, Antonio Scamarcia, Luigi Cantarutti, Vasilisa Sazonov Korcev, Gea Borettto, Carlo Giaquinto, Eugenio Baraldi. (Netherlands)

21 Outcomes of Income-Based Deductibles and Prescription Co-Payments in Older Users of Inhaled Medications [163]
Colin R Dormuth, Malcolm Maclure, Robert J Glynn, Peter Neumann, Alan M Brookhart, Sebastian Schneeweiss. (Canada)

22 Use of Proton Pump Inhibitors and the Risk of Community-Acquired Pneumonia [164]
Sinem Egi Gullmez, Anette Holm, Henrik Frederiksen, Court Pedersen, Jesper Hallas. (Denmark)

23 Herpes Zoster (HZ) Epidemiology and Associated Health Care Use in Olmsted County, MN [165]
Patricia Sakkari, Barbara Yawn, Peter Wollan, Marge Kurland, Linda Sy, James Pellissier, Robbin Itzler. (United States)

24 Adverse Events Associated with Purified Chick Embryo Cell Culture Rabies Vaccine in the United States [166]
Azra Dobardzic, Hector S Izurieta, John Kiskander, Sean Shadomy, Emily J Woo, Charles Ruprecht, Guillermo Herrera, Miles Braun, Robert Ball. (United States)
25 Spontaneous Reports of Breakthrough Varicella in Individuals Vaccinated with VARIVAX™ [Varicella Virus Vaccine Live (Oka/Merck)] [167]

S Galea, A Sweet, R Sharrar, P Beninger. (United States)

26 Evaluating Adverse Events after Vaccination in the Medicare Population [168]

Dale R Burwen, Lawrence La Voie, M Miles Braun, Peter Houck, Rebecca Hudson, Robert Ball. (United States)

27 Post-Licensure Safety Surveillance of Diphtheria, Tetanus Toxoids, Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine Combined (DTaPME) from the U.S. Vaccine Adverse Event Reporting System (VAERS) [169]

Sojo Chang, Karen Fanizo, M Miles Braun, Robert Ball. (United States)

28 Incidence of Congenital Anomalies in the UK [170]

Patrick DeLisle, Paula Long, Kenneth Hornbuckle, Simon Voss. (United Kingdom)

29 Bupropion in Pregnancy and the Prevalence of Congenital Malformations [171]

J Alexander Cole, Kelly S Oh, Claire C Chiang, Sherry M Mentor, Jack G Modell, Barbara R Haught, Irene S Cosmatis, Alexander M Walker. (United States)

30 Use of Selective Serotonin Reuptake Inhibitors in Early Pregnancy and Risk of Cardiac Malformations [172]

M K Bakker, W S Kerstijns-Fredrikse, M D Van den Berg, L TW De Jong-Van den Berg, H EL de Walle. (Netherlands)

31 First Trimester Exposure to SSRIs and the Risk of Birth Defects [173]

Carol Louik, Angela E Lin, Martha M Werler, Sonia Hernandez-Diaz, Allen A Mitchell. (United States)

32 Use of an Insurance Claims Database To Characterize Women Exposed to Bupropion Versus Other Antidepressants during Pregnancy [174]

J Alexander Cole, Kelly S Oh, Claire C Chiang, Jack G Modell, Barbara R Haught, Irene S Cosmatis, Alexander M Walker. (United States)

33 Does Folic Acid Protect Against Heart Anomalies among Children with Down Syndrome? [175]

Willemin M Meijer, Martha M Werler, Carol Louik, Sonia Hernandez-Diaz, Allen A Mitchell. (Netherlands)

34 Gestational Exposure to Paroxetine and Cardiac Malformations in Infants: A Nested Case-Control Study [176]

Anick Berard, Edodie Ramos, Driss Oraichi, Lucie Blais, Evelyne Rey. (Canada)

35 Maternal Use of Oral Contraceptives and Risk of Hypospadias – A Population-Based Case-Control Study [177]

Pa Voegelius, Erzsebet Horvath-Puhó, Lars Pedersen, Mette Nørgaard, Andrew E Czeizel, Henrik Toft Sørensen. (Denmark)

36 GPRD as a Tool for Investigating Teratogenicity [178]

Arlene M Gallagher, Tim J Williams, Tjeerd P van Staa. (United Kingdom)

37 Effective Use of Supplemental Data in a Pregnancy Exposure Registry [179]

Hugh Tilson, Heather Watts, Deborah Covington. (United States)

38 Maternal Use of Erythromycin and Risk of Congenital Malformations: A Population-Based Cohort Study [180]

R W Ogulius, Mette Gislum, Mette Nørgaard, Lars Pedersen, Vera Ehrenstein, Henrik Toft Sørensen. (Denmark)

39 Surveillance of Asthma-Related Drugs during Pregnancy Using a Health Insurance Claims Database [181]


40 Perception of Teratogenic and Foetotoxic Risk by Health Professionals: A Survey in Midi-Pyrenees Area [182]

Juliette Pichereau, Atul Pathak, Isabelle Lacroix, Jean-Louis Montastruc, Maryse Lapreyre-Mestre, Christine Damase-Michel. (France)

41 Optimal Comparison Groups for New User Designs [183]

Robert J Gunn, Soko Setoguchi, Tl Sturmer, Daniel H Solomon, Sebastian Schneeweiss. (United States)

42 Monitoring for Drug Interactions in a Post-Marketing Surveillance Database Using Multi-Item Proportionate Reporting Rate Ratios [184]

Vitali Pool, Brenda Crowe, Sebastian Sorsaburu, Mark E Bangs. (United States)

43 Methods To Pool Infrequent Adverse Event Data: Neutropenia in Rheumatoid Arthritis [185]

Nawab Qizilbash, Emilio Leton, Michael Wiper, Paul Dolin. (United Kingdom)

44 An Approach to Quantifying Confounding by Indication Due to Missing Information [186]

Linda E Levesque, Sophie Dell´Aniello, Amina Barhadi, Sany Suissa. (Canada)

45 Methodological Implications of the Heterogeneity of NSAIDs Users [187]

Abdelilah Abouellahl, Cecile Droz, Nicholas Moore, Fanny Depont, Michel Amouretti, Patrick Blin, Annie Fourrier, The CADEUS Study Team. (France)

46 Modeling Cumulative Dose and Duration of Drug Exposure Using Splines [188]

Marie-Pierre Sylvestre, Michal Abrahamowicz, Robyn Tamblyn. (Canada)

47 Signal Detection Method Taking Seriousness into Account [189]

Takashi Omori. (Japan)

48 Discriminating the Wheat from Chaff: Automated Methods for Separating Safety-Related Signals from Indication-Related Signals in Data Mining Spontaneous Reports [190]

A M Grady, D E Vanderwall, M Yang, D M Fram, W A DuMouchel. (United States)

49 An Analysis of the Exclusion Criteria Used in Observational Pharmacoepidemiological Studies [191]

Michael J Perriolo, Patrick C Waller, Saad AW Shakir. (United Kingdom)

50 The Application of Multiple Imputation Techniques To Identify Missing Cause of Failure [192]

Amir Abbas Tahami Monfared, Elham Rahme, Juhaeri Juhaeri, Rhonda L Bohn. (United States)

51 Factor Analysis as a Tool To Study Metabolic Syndrome as a Predictor of Cardiovascular Disease [193]

(United States)
52 Defining Antibiotic Exposure at the Individual- and Group-Level for Studying Antibiotics as Risk Factors for Acquiring Resistant Nosocomial Infections [194]
Sibel Ascioglu, Marc Lipstich, Matthew H Samore. (United States)

53 Underestimation of Variance Due To Using Simple Random Sampling Statistical Methods Applied to Data Obtained from a Cluster Sampling Design [195]
Jianmin Wang, Amanda Allshouse, William Irish. (United States)

54 Use of Drug Safety Profiling for Assessment of Drug Combinations – A Forgotten Tool? [196]
Andrzej Czarnecki, Simon Voss. (United Kingdom)

55 Instrumental Variables and Survival Outcomes: The Effect of Pancreas-Kidney Versus Kidney Transplantation on Mortality [197]
Edwin P Martens, Wiebe R Pestman, Anthonius de Boer, Svetlana V Belitser, Yves FC Smets, Rudi GJ Westendorp, Olaf H Klungel. (Netherlands)

56 Meta-Analysis with Individually Patient Data of the Efficacy of Oral Naftidrofuryl Versus Placebo in Intermittent Claudication [198]
Tine De Backer, Robert H Vander Stochele, Luc Van Bortel, Philippe Lefert. (Belgium)

57 Approaches to Reducing Confounding by Indication in a Study of Breast Cancer Prognosis in Relation to the Use of Antidepressants after Diagnosis [199]
Jessica Chubak, Denise M Boudreau, Mary Anne Rossing, Noel S Weiss. (United States)

58 Methodologic Considerations in the Evaluation of Sub-Population Specific Therapeutic Effects [200]
Jay S Kaufman. (United States)

59 Survival Analysis with Frailty in the Behavioural Toxicity of Mianserin and Fluoxetine [201]
Alexandre G Silva, Rita Figueirinha. (Portugal)

60 Pseudo-Panel Data Framework: Evidence from the National Health Survey – Portugal [202]
Mónica Inês, Nicoletta Rosati. (Portugal)

61 Patient-Reported Adverse Events Occurring under Asthma Therapy – A Community Pharmacy-Based Survey [203]
Laurent Laforest, Eric Van Garse, Gilles Devouassoux, Brice Kitio, Jacques Massol, Gisèle Bauguil, Geneviève Chamba. (France)

62 Use of the National Hospital Discharge Survey To Understand the Occurrence of Critical Limb Ischaemia and Its Outcome: Planning for Early Drug Development [204]
Joanna F Haas, Kathryn Starzyk, Rhonda L Bohn. (United States)

63 The Use of Individual Risks Rather Than Population Averages in Cost-Effectiveness Modeling [205]
Tjeerd P van Staai, Piet Geusens, Annelies Boonen, Cyrus Cooper, Hubert GM Leufkens. (United Kingdom)

64 A Cohort Study on Effectiveness and Safety of TNF-Blockers in Severe Rheumatoid Arthritis [206]
Marina Maggini, Roberto Rasciutti, Giacomo C Serronetto, Bruno Caffari, Clara Bianchi, Paolo Sfriso, Laura Sottosanti, Silvano Todesco. (Italy)

65 Not All Patients Are Average: The Importance of Epidemiological Data in Pharmacoeconomic Modeling [207]
Tjeerd P van Staai, Annelies Boonen, Piet Geusens, Cyrus Cooper, Hubert GM Leufkens. (United Kingdom)

66 The Effect of Iron Supplementation 2 Times Daily with or without Meals for 12 Weeks in Trimester 2 & 3 Pregnant Women with Iron Deficiency Anemia and Low Heme Diet [208]
Erna Kristin, Mohammad Hakimi, Sri Kadarsh Soejono, Lukman Hakimi. (Indonesia)

67 Abstract Withdrawn [209]

68 ADR-Related Hospitalisations: A Population-Based Cohort Study [210]
Cornelis S van der Hoof, Jeanne P Dieleman, Claire Siemes, Albert-Jan Aarnoudse, Katia MC Verhamme, Bruno H Ch Stricker, Miriam CJM Sturkenboom. (Netherlands)

69 Evaluation of Rapidly Discontinued Medication Orders in a Computerized Physician Order Entry System (CPOE) [211]
Charles E Leonard, Ross Keppel, A Russell Locallo, Abigail Cohen, Brian L Strom. (United States)

70 Concomitant Use of Statins and CYP3A4 Inhibitor Drugs: Data from 380 000 Statin Users [212]
Eileen E Ming, Marcello A Marotti, Sanjay K Gandhi, Pia S Pollack. (United States)

71 Elderly Patients in Stockholm Are Commonly Prescribed Drugs That Require Precautions in Relation to Reduced Renal Function [213]
Ingegerd Odar-Cederlof, Susanne Sjövall, Sten Rönge, Anders Heldén, Anders Soderstrom, Lennart Jacobsson, Lars L Gustafsson, Eva Andersen-Karlsson, Seher Korkmaz, Linus Fred, Ake Nilsson, Ulf Bergman. (Sweden)

72 Effect of Computerized Physician Order Entry with Clinical Decision Support on Adverse Drug Events in the Long-Term Care Setting [214]
Jenny H Gurwitz, Terry Field, Paula Rochon, James Judge, Leslie Harroll, Monica Lee, Kathleen White, Jane Laprino, Janet Erramuspe-Mainard, Martin Delforio, Linda Gaverndo, Chaim Bell, David Bates. (United States)

73 Is Hospitalisation a Determinant for Discontinuity of Drug Use? [215]
Rutger Stuiffken, Eibert E Heerdink, Fred HP de Koning, Patrick C Souriver, Antoine CG Egberts. (Netherlands)

74 Rates of Serious Adverse Events in Patients on High Risk Medications [216]
Joshua P Metlay, Sean Hennessy, Russell Locallo, Charles E Leonard, Jennifer Tija, Abigail Cohen, Kevin Haynes, Wei Yang, Xiaoyan Han, Stephen E Rimmel, Harold I Feldman, Brian L Strom. (United States)

75 Assessment of Preventability of Adverse Drug Effects Detected in an Emergency Department [217]
Marie-Laure Laroche, Séverine Boqueho, Yves Nouaille, Christine Vallejo, Louis Merle. (France)

76 Oral Anticoagulation and Prevention of Bleeding [218]
Stenar Madsen, Bente Werner. (Norway)

77 Adoption of Electronic Prescribing in U.S. Community-Based Medical Practices [219]
Michael A Fischer, Christine Vogeli, Margaret Steedman, Daniel Z Sands, Rainu Kaushal, Joel S Weissman. (United States)
### POSTER SESSION A | Friday, August 25

<table>
<thead>
<tr>
<th>78</th>
<th>Is There a Ratio That Can be Used To Predict Harm from Minor Medication Errors? [220]</th>
</tr>
</thead>
<tbody>
<tr>
<td>79</td>
<td>A Systematic Review of the Nature of Prevalent Adverse Drug Events in Ambulatory Care [221]</td>
</tr>
<tr>
<td>80</td>
<td>A Case-Control Study of the Risk of Cerebrovascular Adverse Events Following Treatment with Antipsychotics in an Elderly Demented Population [222]</td>
</tr>
<tr>
<td>81</td>
<td>The Yellow Card Scheme: Evaluation of Patient Reporting of Suspected Adverse Drug Reactions [223]</td>
</tr>
<tr>
<td>82</td>
<td>Male Infertility and Drug Consumption: Result of a Case-Control Study [224]</td>
</tr>
<tr>
<td>83</td>
<td>Evaluating Telithromycin-Related Hepatotoxicity: an Application of the Case-Control Design to Spontaneous Report Data [225]</td>
</tr>
<tr>
<td>84</td>
<td>An Evaluation of Computer-Aided Disproportionality Analysis for Post-Marketing Signal Detection [226]</td>
</tr>
<tr>
<td>85</td>
<td>Incidence of Drug-Induced Agranulocytosis in Hospital: A Prospective Analysis from Laboratory Signals [227]</td>
</tr>
<tr>
<td>86</td>
<td>Reports of Acute Angle Closure Glaucoma-Related Adverse Events with SSRIs: Results of a Disproportionality Analysis [228]</td>
</tr>
<tr>
<td>87</td>
<td>Standardised MedDRA® Queries: Analysis of Their Signal Detection Capability [229]</td>
</tr>
<tr>
<td>88</td>
<td>Swedish Register-Based Monitoring of Drug Safety in Rheumatoid Arthritis [230]</td>
</tr>
<tr>
<td>89</td>
<td>Abstract Withdrawn [231]</td>
</tr>
<tr>
<td>90</td>
<td>Accelerated Reporting of Vaccine Adverse Events: A Novel Approach for Enhanced Pharmacovigilance [232]</td>
</tr>
<tr>
<td>91</td>
<td>Prescription-Event Monitoring Study of Oxcarbazepine as Used in General Practice in England [233]</td>
</tr>
<tr>
<td>92</td>
<td>Low-Potency and Atypical Antipsychotics Were Associated with Pulmonary Embolism among Swedish Autopsy Cases [234]</td>
</tr>
<tr>
<td>93</td>
<td>Post-Marketing Hepatic Adverse Event Reporting in the EU, Japan and USA [235]</td>
</tr>
<tr>
<td>94</td>
<td>Relationship between Drug-Drug Interactions and Adverse Drug Effects: A Case-Control Study [236]</td>
</tr>
<tr>
<td>95</td>
<td>Comparing Data Mining Algorithms in Pharmacovigilance: Points To Consider for Prospective Surveillance [237]</td>
</tr>
<tr>
<td>96</td>
<td>Spontaneously Reported Fatal Adverse Drug Reactions: A 10-Year Survey from Sweden [238]</td>
</tr>
<tr>
<td>97</td>
<td>The Pharmacoepidemiology of Carisoprodol Misuse and Abuse [239]</td>
</tr>
<tr>
<td>98</td>
<td>Spontaneous Reports of Asthma-Related Adverse Events with Acetaminophen: Results of a Disproportionality Analysis [240]</td>
</tr>
<tr>
<td>99</td>
<td>A Statistical Approach To Duplicate Detection in Adverse Drug Reactions Monitoring [241]</td>
</tr>
<tr>
<td>100</td>
<td>The Relation Between Hepatitis B and Demyelinating Diseases: A Data Mining Analysis of a Phantom Ship Association in VAERS [242]</td>
</tr>
<tr>
<td>101</td>
<td>Using Report Quality Indicators Increases Power for Safety Signal Detection [243]</td>
</tr>
<tr>
<td>102</td>
<td>Illusion of Objectivity and Recommendations for Reporting Data Mining Results [244]</td>
</tr>
<tr>
<td>103</td>
<td>Drowsiness and Sedation: A Comparison Between Levocetirizine and Desloratadine Using Post-Marketing Observational Data from Prescription-Event Monitoring (PEM) Studies [245]</td>
</tr>
<tr>
<td>104</td>
<td>Anaphylactoid Reactions to Dextran 40 and 70: Reports to the US Food and Drug Administration (FDA) [246]</td>
</tr>
<tr>
<td>105</td>
<td>Adverse Drug Reaction Reporting by Dispensing Pharmacists in Norway – A Pilot Study [247]</td>
</tr>
<tr>
<td>106</td>
<td>Intervention To Improve Adverse Drug Reaction Reporting: A Cluster-Randomized Trial among Portuguese Pharmacists [248]</td>
</tr>
<tr>
<td>ID</td>
<td>Title</td>
</tr>
<tr>
<td>----</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>107</td>
<td>Using Semantic Distance for Clustering ADR Case Reports with the WHO-ART Classification</td>
</tr>
<tr>
<td>109</td>
<td>Creation of a Pharmacovigilance Control Project in a Private Health Service</td>
</tr>
<tr>
<td>110</td>
<td>Signal Detection in the Evaluation of Bisphosphonate-Associated Osteonecrosis of the Jaw</td>
</tr>
<tr>
<td>112</td>
<td>Mapping of the WHO-ART Terminology on Snomed CT To Improve Grouping of Related Adverse Drug Reactions</td>
</tr>
<tr>
<td>113</td>
<td>Abstract Withdrawn</td>
</tr>
<tr>
<td>114</td>
<td>A Preliminary Comparison of the FDA-AERS Database and WHO Adverse Events Database for Purpose of Data Mining</td>
</tr>
<tr>
<td>115</td>
<td>A Pilot To Assess the Potential of Clinical Trials Data To Predict Postmarketing Signals of ADRs</td>
</tr>
<tr>
<td>116</td>
<td>Comparison of the Quality of Spontaneous Adverse Drug Reaction Reports Received from Consumers Versus Healthcare Professionals in 2003</td>
</tr>
<tr>
<td>117</td>
<td>Impact of Patient Outreach Programs on Consumer Reports of Adverse Events</td>
</tr>
<tr>
<td>118</td>
<td>Knowledge Acquisition for Formal Definitions of WHO-ART Terms</td>
</tr>
<tr>
<td>119</td>
<td>Reports of Hyperkalemia after Publication of Rales – A Pharmacovigilance Study</td>
</tr>
<tr>
<td>120</td>
<td>Influence of Underreporting on Statistical Measures in Signal Detection</td>
</tr>
<tr>
<td>121</td>
<td>Assessment of Adverse Drug Reactions Reports Related to Pediatric Patients Sent to Pharmacovigilance Unit</td>
</tr>
<tr>
<td>122</td>
<td>Reporting of Adverse Drug Reactions To Complimentary and Alternative Medicines – Experiences and Results from an Indian Tertiary Care Hospital</td>
</tr>
<tr>
<td>123</td>
<td>Pattern of Adverse Drug Reactions Notified by Spontaneous Reporting in an Indian Tertiary Care Teaching Hospital</td>
</tr>
<tr>
<td>124</td>
<td>Cardiovascular Safety of Tadalafil in a Cohort of Users in England</td>
</tr>
<tr>
<td>125</td>
<td>Spontaneous Reports of Adverse Drug Reactions: A Retrospective Analysis Using the Portuguese Southern Regional Pharmacovigilance Unit Database</td>
</tr>
<tr>
<td>126</td>
<td>Potential Use of Data Mining Algorithms for the Detection of “Surprise” Adverse Drug Reactions</td>
</tr>
<tr>
<td>127</td>
<td>Alpha-1 Proteinase Inhibitor (Human) Product Postmarketing Safety Surveillance</td>
</tr>
<tr>
<td>128</td>
<td>Postmarket Adverse Event Reporting Rates: How Well Do They Approximate Incidence Estimates</td>
</tr>
<tr>
<td>129</td>
<td>Adverse Effects of Medications in Portugal. A Preliminary Analysis of Hospital Discharge Data</td>
</tr>
<tr>
<td>130</td>
<td>Pharmacovigilance and Pharmacoepidemiology of Gastric Acid Suppressants and Risk of C. difficile Colitis: Scientific Developments at the Interface of Clinical Medicine and Public Health</td>
</tr>
<tr>
<td>132</td>
<td>Risk of Selected Outcomes among the Solid Organ Transplant Patients: A Systematic Literature Review</td>
</tr>
<tr>
<td>133</td>
<td>A Data Mining Analysis in Two Spontaneous Reporting System Databases Using Placebo-Associated Adverse Events as “True Negatives”</td>
</tr>
<tr>
<td>135</td>
<td>Paracetamol Adverse Reactions Notified to the Northern Portugal Pharmacovigilance Unit by an Immunology Health Department</td>
</tr>
</tbody>
</table>
Submit your papers to
Pharmacoepidemiology and Drug Safety

online

Saving you time and money, the online manuscript submission, tracking and peer-review service is the new way to submit your papers.

- No need for 3 copies and expensive photos – simply upload text and images
- No time waiting for the post – all correspondence is via e-mail
- Check the status of your manuscript at any time and from anywhere in the world
- View and respond to reviewers’ comments and submit revisions instantly
- PDF proofs of accepted papers are sent by e-mail for faster processing

For further information, visit the ‘For Authors’ section on the journal homepage: www.interscience.wiley.com/journal/pds

Would you like to contribute to the success of Pharmacoepidemiology and Drug Safety?
Why not become a reviewer?

In response to the increasing number of submissions to PDS, we wish to expand our panel of reviewers. By making a substantial contribution to the development of the subject, reviewers are key to the progressive improvement of our journal. If you are interested in reviewing for PDS and have appropriate expertise, we would like to hear from you.

For further details please contact
Professor Ron Mann, Editor-in-Chief (ronmann@professormann.com) and
Professor Brian Strom, Editor for the Americas (bstrom@cceb.med.upenn.edu)

WILEY InterScience®
DISCOVER SOMETHING GREAT
163 Characteristics of French Women Presenting with Urinary Incontinence, Baseline Results from the PURE Study (Prospective Urinary Incontinence Research) [305]
Emmanuel Chartier-Kastler, Stephanie Tcherny-Lessenot, Sandra Avoinet, Brigitte Bosio-Le Goux. (France)

164 Migraine Incidence, Comorbidities and Health Resource Utilization in the United Kingdom [306]
Claudia Becker, Gunnar Brobert, Per Almqvist, Saga Johansson, Susan S Jick, Christoph R Meier. (Switzerland)

165 Angiotensinogen M235T Polymorphism and the Risk of Myocardial Infarction and Stroke among Hypertensive Patients on ACE-Inhibitors or beta-Blockers [307]
Hedi Schelleman, Olaf H Klungel, Jacqueline CM Witteman, Monique MB Breteler, Jan HJ Danser, Albert Hofman, Cornelia M van Duijn, Anthonius de Boer, Bruno HCh Stricker. (Netherlands)

166 Identifying Nonresponders to Asthma Therapy Using Leukocyte Parameters [308]
Karin J Velthove, Madelon Bracke, René C Schweizer, Maarten J ten Berg, Hubert GM Leufkens, Wouter W van Solinge. (Netherlands)

167 Is Use of Asthma Medication in Preschool Children Consistent with the Clinical Wheezing Phenotype? [309]
Mira G Zuidgeest, Madelon Bracke, Henriette A Smit, Bert Brunekreef, Hubert G Leufkens. (Netherlands)

168 Drug Utilisation Study of the Newer Antiepileptic Drugs in Children – Preliminary Results Using the General Practice Research Database (GPRD) [310]
Ruth Ackers, Macey Murray, Frank Besag, Ian Wong. (United Kingdom)

169 Antiepileptic and Psycholeptic Drugs Used in ADHD (Attention Deficit / Hyperactivity Disorder) in Addition to Methylphenidate [311]
Edda Wuermeng, Katrin Janhsen, Gerd Glaeske. (Germany)

170 Incidence, Prevalence, and Demographic Differences in Central Nervous System Stimulant (CNSS) Use in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD). A Study of Florida Medicaid Beneficiaries 1994-2004 [312]
Tobias F Gerhard, Almut, G Winterstein, Jonathan J Shuster. (United States)

171 The Use of Anti-Asthmatic Medications among Children in Salvador, Brazil [313]
Djanilson B Santos, Mauricio L Barreto, Helena Lutescia L Coelho. (Brazil)

172 A Time-Trend Analysis of All Clinical Activity, Amoxicillin/Co-Amoxiclav Prescribing, Acute Otitis Media and Acute Mastoiditis in Paediatrics in General Practice [314]
Paula L Thompson, Ruth Gilbert, Paul Long, Macey L Murray, Mike Sharland, Ian CK Wong. (United Kingdom)

173 Drug Utilization in Hospitalized Children in Fortaleza, Brazil [315]
Djanilson B Santos, Ana Lucia F Veneranda, Helena Lutescia L Coelho. (Brazil)

174 Lack of Medicines with Proper Formulation for Use in Children and Its Practical Repercussions in a Reference Pediatric Public Hospital in Fortaleza, Brazil [316]
Helena Lutescia L Coelho, Patricia Q da Costa, Janete Elisa S de Lima. (Brazil)

175 Pediatric Medication with Homeopathic and Herbal Drugs in the Survey for Children and Adolescents in Germany – The Heritage of Samuel Hahnemann [317]
Hans-Ulrich W Melchert, Knopf Hildtraud, Yong Du, Marianne Braemer-Hauth, Ellen Pabel. (Germany)

176 Study of Prescription Practice of Antipyretics for Pediatric Patients in Ambulatory Care in Bulgaria [318]
Ilko N Getov, Nikolay Kolev, Maria Nedialkova, Krassimir B Iliev. (Bulgaria)

177 Appropriate Use of Chemotherapy for Cancer in Day-Hospital Settings in Italy [319]
Ambrogio Bottini, Andrea Lanza, Cristina Meneghin, Giovanna Brusco, Giovambattista Ippoliti. (Italy)
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Attention Deficit/Hyperactivity Disorder: A Preliminary Study in the Nelson Mandela Metropole [320]</td>
<td>Samnari Snyman, Ilse Truter, Marosé Ferreira. (South Africa)</td>
</tr>
<tr>
<td>2</td>
<td>Abstract Withdrawn [321]</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Information Lost on Aggregating Consumption Data: Calcitoxin in Valencian Community, Spain (2000-2004) [325]</td>
<td>Fernando Fernandez-Llimos, Laura Monzon, Marta Colomer, Rocio Broseta, Amalía Ubeda. (Spain)</td>
</tr>
<tr>
<td>7</td>
<td>Antihyperglycemic Prescribing Trends for Patients with Type 2 Diabetes in Italy: A Descriptive Study in Primary Care [326]</td>
<td>Giampaolo Mazzaglia, Nicole Yurgin, Kristina Secnik, Gerardo Medea, Claudio Cricelli. (Italy)</td>
</tr>
<tr>
<td>9</td>
<td>Descriptive Study and Pharmacotherapeutic Advisory Intervention at a Medicine Clinic of a Large Hospital in Stockholm [328]</td>
<td>Buster Mannheimer, Johanna Ulfvarson, Monica Bergqvist, Christer von Bahr. (Sweden)</td>
</tr>
<tr>
<td>10</td>
<td>Nurses’ Attitudes to Medication Care in Nursing Homes. Results of the PHEBE Project [329]</td>
<td>Monique M Elseviers, Tom Deffoor, Robert H Vander Stichele. (Belgium)</td>
</tr>
<tr>
<td>12</td>
<td>Polypharmacy in a Danish County [331]</td>
<td>K Schaeffer, L O Henriksen, H Maerkedahl. (Denmark)</td>
</tr>
<tr>
<td>13</td>
<td>The Effect of Quality Incentives in General Practice: Observations on Prescribing Patterns Using the Defined Daily Dose Method [332]</td>
<td>Sean P MacBride-Stewart, Tom Walley. (United Kingdom)</td>
</tr>
<tr>
<td>14</td>
<td>Prevalence of Drug Treatment in Subjects with Alzheimer’s Disease in France [333]</td>
<td>Antoine Pariente, Catherine Helmer, Nicholas Moore, Annie Fourrier, Jean-François Dartigues. (France)</td>
</tr>
<tr>
<td>15</td>
<td>Prevalence of Drug Treatment in Subjects with Alzheimer’s Disease in Europe [334]</td>
<td>Antoine Pariente, Catherine Helmer, Annie Fourrier, Nicholas Moore, Jean-François Dartigues. (France)</td>
</tr>
<tr>
<td>16</td>
<td>Drug Utilization Review: Combination Therapy in Asthma [335]</td>
<td>Marie-Claude Breton, Jacques Le Lorier, Amelie Forget, Lucie Blais. (Canada)</td>
</tr>
<tr>
<td>17</td>
<td>Risk of Lower Respiratory Tract Infection among Users of Inhaled Corticosteroids [336]</td>
<td>Marc Dorais, Jacques Le Lorier. (Canada)</td>
</tr>
<tr>
<td>19</td>
<td>Non-Steroidal Anti-Inflammatory Drug Prescription in Relation to the Prescribing of Gastroprotective Drugs in Australia [338]</td>
<td>Nadia Barozzi, Susan Tett. (Australia)</td>
</tr>
<tr>
<td>20</td>
<td>Renal Risk Drugs Are Widely Used in Hospitalised Patients with Impaired Renal Function [339]</td>
<td>Hege S Blix, Kirsten K Viktul, Tron A Moger, Aasmund Reikvam. (Norway)</td>
</tr>
<tr>
<td>22</td>
<td>Early Identification of Long Term Poor Compliance in Ambulatory Patients Using a Multivariate Risk Score Model [341]</td>
<td>Harm CI Geers, Cornelia J de Blaey, Antoine CG Egberts, Elber R Heerdink. (Netherlands)</td>
</tr>
<tr>
<td>23</td>
<td>The Ever Increasing Use of Proton Pump Inhibitors in Norway [342]</td>
<td>Christian Berg, Kari Furu. (Norway)</td>
</tr>
<tr>
<td>28</td>
<td>Predictors of Appropriate Use of Anti-Asthma Drugs among Individuals Aged 12 to 45 Years [347]</td>
<td>Marie-Sophie Jobin, Jocelyne Moisan, Yves Bolduc, Eileen Dorval, Madame Turcotte, Jean-Pierre Gregoire. (Canada)</td>
</tr>
<tr>
<td>29</td>
<td>Prescription Patterns of Major Antidepressant Drugs in Adults Diagnosed with Depression: A GPRD-Based Study [348]</td>
<td>Sebastien Bineau, Delphine Saragossi, Nicolas Despiegel, Mondher Toumi, Patrice Verpillat. (France)</td>
</tr>
<tr>
<td>30</td>
<td>Indications for Antidepressant Drug Prescribing in General Practice in the Netherlands [349]</td>
<td>Helga Gardarsdottr, Elber R Heerdink, Liset van Dijk, Antoine CG Egberts. (Netherlands)</td>
</tr>
<tr>
<td>Poster Session B</td>
<td>Saturday, August 26</td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------------</td>
<td></td>
</tr>
<tr>
<td>59 Patients’ Awareness of Medicine Indications [378]</td>
<td>Ermelindo Fontes, Sofia Couto, Zilda Mendes, Ana Miranda. (Portugal)</td>
<td></td>
</tr>
<tr>
<td>60 Utilization of Anti-Platelet Drugs in Portugal [379]</td>
<td>Ermelindo Fontes, Sofia Couto, Jose Guerreiro. (Portugal)</td>
<td></td>
</tr>
<tr>
<td>63 Short-Lived Influence on Prescribing Trends Following Publication of the ALLHAT Trial [382]</td>
<td>Patricia A Caetano, Steven G Morgan, Colette Raymond, Ken Bassett. (Canada)</td>
<td></td>
</tr>
<tr>
<td>64 Pharmacoepidemiology of Drug Use at Clinics of University Teaching Hospital in Novi Sad, Serbia and Montenegro [383]</td>
<td>Zdenko Tomic, Ana Sabo, Zoran Bokumiric, Olga Horvat, Slavica Canak, Vida Jakovic. (Yugoslavia)</td>
<td></td>
</tr>
<tr>
<td>65 Benzodiazepine’s Utilization in Continental Portugal (1999-2004) [384]</td>
<td>Ines Teixeira, Claudia Furtado. (Portugal)</td>
<td></td>
</tr>
<tr>
<td>66 Repetition of Pharmacotherapy Key Messages in a Social Marketing Program To Improve Prescribing [385]</td>
<td>Judith M Mackson, Fiona E Horn, Debra Rowett, Gwen Higgins, Lynn M Wekes. (Australia)</td>
<td></td>
</tr>
<tr>
<td>67 Fifteen Years of Pharmaceutical Expenditures in Belgium from 1990 to 2004 [386]</td>
<td>Robert H Vander Stichele, Rudy Van Tielen. (Belgium)</td>
<td></td>
</tr>
<tr>
<td>68 Drug Rationalization at the Clinics in University Teaching Centre Novi Sad: Introducing the Delivery of Daily Doses of the Drugs to Hospital Departments [387]</td>
<td>Ana Sabo, Zdenko Tomic, Goran Marusic, Dragan Draskovic, Jan Varga, Ivana Krajcic. (Yugoslavia)</td>
<td></td>
</tr>
<tr>
<td>70 Utilization of Statins in Portugal [389]</td>
<td>Ermelindo Fontes, Zilda Mendes. (Portugal)</td>
<td></td>
</tr>
<tr>
<td>71 Setting a Criterion and a Standard for Prescribing Quality Indicators in Antibiotic Therapy in Ambulatory Care: Mind the Gap When Dabbling in the Dark [390]</td>
<td>Pierre Chevalier, Henk Van Den Broele, Robert H Vander Stichele, Monique M Elseviers. (Belgium)</td>
<td></td>
</tr>
<tr>
<td>72 Non Prescription Antibiotic Use in Hungary [391]</td>
<td>Maria Matuz, Ria Benko, Peter Doro, Edit Kosik, Edit Polgar, Gyongyver Soos. (Hungary)</td>
<td></td>
</tr>
<tr>
<td>73 Antidepressant Utilization in British Columbia, Canada [392]</td>
<td>Colette Raymond, Patricia A Caetano, Steven G Morgan. (Canada)</td>
<td></td>
</tr>
<tr>
<td>74 Pattern of Use of Statins in Portugal [393]</td>
<td>Ermelindo Fontes, Sofia Couto, Zilda Mendes, Paula Martins, Ana Miranda. (Portugal)</td>
<td></td>
</tr>
<tr>
<td>75 Change of Hormone Replacement Therapy Usage in Canada before and after the Publication of the Women’s Health Initiative Studies [394]</td>
<td>Yipu Shi, Shi Wu Wen, Mark Walker, Chris Robinson. (Canada)</td>
<td></td>
</tr>
<tr>
<td>76 Impact of Institutional Determinants on Prescribing Quality: Results of the PHEBE Project [395]</td>
<td>Robert H Vander Stichele, Kris Soenen, Monique M Elseviers, Micheline Gobert, Pierre Chevalier. (Belgium)</td>
<td></td>
</tr>
<tr>
<td>78 Appraisal and Compliance Behaviour among Patients in Lipid-Lowering Drug Treatment [397]</td>
<td>John Larsen, Lina Falde. (Denmark)</td>
<td></td>
</tr>
<tr>
<td>80 How We Imagine a Drug? Maximizing Placebo Effect of Active Treatments [399]</td>
<td>Ana M Macedo, Josep E Banos, Magi Farre. (Spain)</td>
<td></td>
</tr>
<tr>
<td>84 The Optimal Content and Format of Prescription Drug Labels: A Systematic Review of the Literature [403]</td>
<td>William H Shrank, Jerry Avorn, Cory Rolon, Paul Shekelle. (United States)</td>
<td></td>
</tr>
<tr>
<td>85 Utilisation and Expenditure of Lipid Lowering Drugs in Finland, Ireland and Sweden. Effect of Generic Substitution [404]</td>
<td>Jaana E Martikainen, Björn Wettermark, Lesley H Tilson. (Finland)</td>
<td></td>
</tr>
<tr>
<td>86 Use of Administrative Data To Observe the Cost and Prescribing Patterns for Mental Health Care in a Medicaid Population [405]</td>
<td>Thomas J Bunz, Brian J Quilliam, Rita M Marcoux, E Paul Larrat. (United States)</td>
<td></td>
</tr>
<tr>
<td>87 Physician Sources and Perceptions of Drug Risk Communication [406]</td>
<td>Elaine H Morrato, Barbara Curbow, Carolyn Nowels, Manning Feinleib. (United States)</td>
<td></td>
</tr>
</tbody>
</table>
90 The Role of Litigation in Defining Drug Risks [409]
Aaron S Kesselheim, Jerry Avorn. (United States)

91 British Columbian Physicians’ Beliefs Regarding Reference Drug and Generic Substitution Programs [410]
Jennifer M Polinski, Malcolm MacInlay, Blair Marshall, Alan Cassels, Jessica Agnew-Blais, Amanda Patrick, Sebastian Schneeweiss. (United States)

92 Impact of Sequential Pharmacy Benefit Changes on Health Outcomes in a PPO [411]
Thomas K Hazel, Elizabeth B James, David K Blough. (United States)

93 The Impact of Cost-Sharing on Antidepressant Use in Older Adults [412]
Amanda R Patrick, Sebastian Schneeweiss, Colleen R Dormuth, Malcolm MacInlay, Philip S Wang. (United States)

94 How Do Practitioners Prescribe Drugs That Can Be Replaced by Generics in Portugal? [413]
José P Guerreiro, Ermelindo Fontes, Zilda Mendes. (Portugal)

95 Exploring Hypothesis for Explaining Differences on Generic Prescription Profiles [414]
José P Guerreiro, Ermelindo Fontes, Zilda Mendes. (Portugal)

96 Impact of the Exception Drug Status on Access to Clopidogrel in Quebec [415]
Odile Sheehy, Stéphane Rinfret, Jacques LeLorier. (Canada)

97 Income-Based Drug Coverage in British Columbia: The Impact on Access to Medicines [416]
Patricia A Caetano, Colette Raymond, Steven G Morgan, Gillian Hanley. (Canada)

98 Orphan Medicines’ Therapeutic Profile [417]
Carla Teneira de Barros. (Portugal)

99 Sleep Disorders Are Associated with Psychiatric and Gastrointestinal Diseases in Primary Care [418]
Mari-Ann Wallander, Saga Johansson, Ana Ruigomez, Luis A Garcia Rodriguez. (Sweden)

100 The Role of Gastrointestinal Morbidity in Abdominal Pain [419]
Mari-Ann Wallander, Saga Johansson, Ana Ruigomez, Luis A Garcia Rodriguez. (Sweden)

101 Medicine Poisoning in Portugal: A Preliminary Analysis of Hospital Discharge Data [420]
Pedro Marques-Vidal, Sara Marques-Vidal, Carlos Matias Dias. (Portugal)

102 Variability across U.S. Medicaid Prior Authorization Programs for Anti-Depressants [421]
Jennifer M Polinski, Philip Wang, Amber Servi, Elizabeth Robinson, Michael Fischer. (United States)

103 Prescriptions of Non Steroidal Anti-Inflammatory Drugs during Pregnancy in 2003-2004 in Midi-Pyrenees Area [422]
Caroline Hurault, Isabelle Lacroix, Robert Bourrel, Maryse Lapeyre-Mestre, Jean-Louis Montastruc, Christine Damase-Michel. (France)

104 Disparities in the Use of Anti-Hypertensive Medication in a Multiethnic Population in Southern Sweden [423]
Farhad A Khan, Rosvall Maria, Mathias Nilsson, Per-Olof Östergren. (Sweden)

105 Performance-Enhancing Drug Use by Students during Examination Periods [424]
Maryse Lapeyre-Mestre, Eva Lapaix. (France)

106 Osteoporosis Screening, a Health Promotion Initiative in Portuguese Community Pharmacies [425]
Isabel Oliveira, Sofia Figueiredo, Brenda Madureira. (Portugal)

107 Impact of a Dyslipidemia Management Workshop on Community Pharmacists’ Knowledge: TEAM Workshop [426]
Julie Villeneuve, Jacques Genest, Diane Lamarre, Marie-Claude Vanier, Sylvie Perreault, Lucie Biais, Marie-Theerese Lussier, Evelyne Hudon, Lyne Lalonde. (Canada)

108 Effect of Isoniazid Prophylaxis for Tuberculosis in Adults with Anergy and HIV Infection. An Updated and Improved Meta-Analysis of Randomized Controlled Trials [427]
Hwee-Ting Tsai. (United States)

109 Adherence to Chronic Medication in Dutch Primary Care [428]
Liset van Dijk, Dinesh Somai, Elibert Heerink, Sandra van Dulmen, Emmy Suijs, Denise De Ridder, Jozien Bensing. (Netherlands)

110 Risk of Systemic Adverse Effects and Nasal Perforation with Fluticasone Propionate as Compared to Other Inhaled Nasal Steroids [429]
Stephen P Motykio, Marlo A Corrao, Ruby M Vendola, Kourtney J Davis, Earl L Goehring, Judith K Jones. (United States)

111 Beyond Dispensing: What Pharmacists Do To Intervene To Improve Outcomes of Nursing Home Residents? [430]
Kate L Lapane, Brian J Quilliam, Carmel M Hughes. (United States)

112 Is the Use of Information Technology Feasible To Exchange Information among Pharmacists Providing Care for Nursing Home Residents? [431]
Kate L Lapane, Carmel M Hughes, Janice L Feinberg. (United States)

113 “Assessment of Hospital Pharmacies in Brazil”: A Propose for Classification of Services [432]
Ana M Messeder, Claudia GS Osorio-de-Castro, Luiz AB Camacho. (Brazil)

114 Evaluation of Cardio and Cerebrovascular Disease Risk in Portugal [433]
Ana Macedo, Ana Santos. (Portugal)

115 Adverse Drug Reactions Suffered by University Students [434]
Ramona Mateos-Campos. (Spain)

Katrin Janhsen, Gerd Glaeske. (Germany)

117 The Relation between the Use of Psychoactive Substances and Injury Severity within a Group of Crash Involved Drivers [436]
Beatrice E Skrinik, Kris LL Movig, Klaus J Lusthof, Johan I De Geer, Donald RA Liges, Antoine CG Egberts. (Netherlands)

118 Health Care Utilization of Patients with Chronic Low Back Pain in Germany, A Study Based on Administrative Health Care Data [437]
Ingrid Schubert, Ingrid Koester, Peter Fiel. (Germany)
120 Epidemiology, Treatment, and Costs of Osteoporosis in Germany – The BoneEVA-Study 1391
Sandra Mangapane, Holger Gothe, Ariane Hoer, Bertram Haussler. (Germany)

121 Clinical Trials and Nails [440]
Javier Cid Ruzafa, Ana M Rueda de Castro, William I Holden. (Spain)

122 Inappropriate Benzodiazepine Use in Older Adults and the Risk of Fracture [441]
Cornelis S van der Hooft, Mariette W Schoofs, Gijsbertus Ziere, Albert Hofman, Huibert A Pols, Miriam C Sturkenboom, Bruno H Stricker. (Netherlands)

123 Relationships between Full-Fill Rate of Quality Indicators of Pharmacologic Therapy and Mortality of Patients with Acute Myocardial Infarction in a Medical Center [442]
Chen-fang Lin, Chun-yu Wang. (Taiwan)

124 A Cost-Effectiveness Analysis (CEA) of 3 Interventions To Enhance Medication Laboratory Monitoring [443]
David H Smith, Adrienne Feldstein, Nancy Perrin, Xiuhai Yang, Rx Mary, Marsha Raebel, David Magid, Steven Simon, Stephen Soumerai. (United States)

125 Health Outcomes of High Cost Pharmaceutical Users [444]
Anita L Kozirsky, Matthew E Dahl, Songul Boaz. (Canada)

126 Does the Introduction of an Incentive Based Contract Ensure Equity of Treatment of Patients with Stroke in Scottish Primary Care? [445]
Colin R Simpson, Philip C Hannaford, Karen Lefevre, David Williams. (United Kingdom)

127 European Surveillance of Antimicrobial Consumption (ESAC): Quality Indicators of Antibiotic Prescribing in Ambulatory Care [446]
Matus Ferech, Samuel Coenen, Erik Hendrickx, Carl Suetsens, Surbhi Malhotra-Kumar, Herman Goossens, ESAC Project Group. (Belgium)

128 QUADRI: A National Survey of the Quality of Care for Diabetic Persons in Italy [447]
Marina Maggini, Valero Aprile, Sandro Baldissera, Angelo D’Argenzio, Salvatore Lopresti, Oscar Mingozzi, Salvatore Scondotto, Alberto Perra, Ylka Lodra, Bruno Caffari, Nancy Benkin. (Italy)

129 Prospective Observational Study of Adverse Drug Reactions (ADR) in an Internal Medicine Department [448]
Luis S Pinheiro, Vasco Al Maria, Margarida Lucas, Rui MM Vitorino. (Portugal)

130 The Impact of Revised Practice Guidelines on Prescribing Drugs in the Treatment of Type 2 Diabetes Mellitus [449]
Rene Lub, Petra Denig, Paul van den Berg, Kaas Hoogenberg, Lolkje de Jong-van den Berg. (Netherlands)

131 Use of Indicators To Evaluate the Quality of Care in Hospitalized Adults with Community-Acquired Pneumonia [450]
S A Ratchina, E P Shal, A S Frolova, S A Guljaeva. (Russian Federation)

132 Influence of Generic Substitution on Drug Sales Pattern [451]
Karolina Andersson, Max G Petzold, Peter Allebeck, Anders Carlsten. (Sweden)

133 The Impact of Medicinal Authority’s Warnings on the Prescribing of SSRI Antidepressants to Children and Adolescents in Norway [452]
Jørgen G Bramness, Anders Engeland, Kari Furu. (Norway)

134 Quality Assessment of ADR-Reports on Generic Substitution Related to Early Signal Identification [453]
Anne Bee Hegge, Linda Amundstuen, Anna Lillesfjøth, Hanne Stenberg-Nilsen, Pernille Harg. (Norway)

135 Rationalization of Pharmaceuticals Utilization by Means of Drug Formulary: The Pilot Project in Belarussian Multiprofile Hospital [454]
Maxim N Mily, Marina M Sachek, Vladimir V Lugovoy, Sergey A Golubev. (Belarus)

136 A Way To Improve Compliance with an Osteoporosis Treatment: Setting up of a Patient Education Program [455]
Christian Roux, Bertrand Cortet, Stephanie Tcherny-Lessenot, Priscille Poitrinal, Soyi Liu-Leage. (France)

137 Utilisation of Anti-Rheumatic Drugs in Australia: Impact of Introducing High-Cost Biologics under the Pharmaceutical Benefits Scheme [456]
Christine Y Lu, Ken M Williams, Ric O Day. (Australia)

138 Access to High-Cost Medicines for the Treatment of Rheumatoid Arthritis under Australia’s Pharmaceutical Benefits Scheme [457]
Christine Y Lu, Ken M Williams, Ric O Day. (Australia)

139 Postmarket Surveillance of Drug-Eluting Stents [458]
Hesha J Duggirala, David E Kandzari, Thomas P Gross. (United States)

140 Are Drugs a Risk Factor for Heat-Related Hospitalisation? [459]
Karin Martin, Marie-Pierre Gourcy, Claude Gabinsky, Isabelle Faure, Bernard Begaud, Philippe Latry, Helene Verdoux. (France, Metropolitan)

141 Comparison of Data from a US National Survey (NHANES) with Data from a Cohort Recruited from the Internet [460]
Alicia Gilsenan, Xiaolei Zhou, Florence Coste, Amanda Allshouse. (United States)

142 Rosuvastatin Similar to Other Statins with Respect to Muscle-Related, Renal, and Hepatic Adverse Events [461]
Andrew T McKinzie, Eileen E Ming, John D Seeger, Sherry G Quinn, Eva W Ng, Jared D Danielson, Jennifer A Cutone, Jonathan C Fox, Alexander M Walker. (United States)

143 Risk of Intravitreous Injection-Related Endophthalmitis in Patients with Age-Related Macular Degeneration (AMD) in the US Medicare Population [462]
Jingping Mo, Yinkang Duan, Manju Patel, Ronald Klein, Ingrid U Scott, Kui Huang, Duanping Liao. (United States)

144 Use of Herbal/Natural Supplements According to Racial/Ethnic Group [463]
Judith P Kelly, David W Kaufman, Lynn Rosenberg, Allen A Mitchell. (United States)

145 Use of the Registry Methodology in a Rare Disease Setting: The Familial Adenomatous Polyposis (FAP) Registry-Based Study [464]
L Gutierrez, E Moy, C Eagle. (Spain)
POSTER SESSION B | Saturday, August 26

146 A New Register on Prescribed Pharmaceuticals in Sweden [465]
Andrejs Leimanis, Björn Wettermark, Niklas Hammar, Michael Fored, Petra Otterblad Olausson, Måns Rosén. (Sweden)

147 Pharmacovigilance Regional Centres – The Suitable Model for Small Countries? [466]
S Gonçalves, A Araújo, M Lemos, S Queiroz, E Teófilo, J R Silva, R Carmona. (Portugal)

148 Extent of Pharmacoepidemiology Education in U.S. Schools of Pharmacy [467]
Esmond D Nwokeji, Karen I Rascati, Tish R Moczygemba, James P Wilson. (United States)

149 Intervention with Outreach Visits To Change Prescription Patterns in General Practice in the County of Aarhus, Denmark [468]
Pia Ehlers, Inger Kristiansen, Jørgen N Nielsen, Hanne Nielsen, Jens Søndergaard. (Denmark)

150 Quantifying the Amount and Cost of Wasted Medicines in Portugal [469]

151 Refill Persistence with Oral Antidiabetic Therapy in Hungary [470]
Peter Doro, Ria Benko, Edit Kosik, Maria Matuz, Katalin Toth, Gyongyver Soos. (Hungary)

152 Cardiovascular Risk Factors in Patients Diagnosed with Stage III or IV Breast Cancer Treated with Cardiotoxic and Non-Cardiotoxic Regimens [471]
Marianne Ulcickas Yood, Annette Beiderbeck, Jacquelyn Saltzgaber, Susan A Oliveria. (United States)

153 Verification of Observational Data Using GPRD [472]
Tim J Williams, Tarita Murray-Thomas, Brendon Ambersley. (United Kingdom)

154 The Direct Relationship between Childhood Health and Elderly Self-Rated Health [473]
Mark A Allen. (United States)

155 Assessment of Exposure to the Excipients Benzyl Alcohol (BA) and Propylene Glycol (PG) in Critically Ill Neonates [474]
Nadine Shehab, Carrie I Mukahill, Darcie D Streetman. (United States)

END SESSION B
1 All-Cause Mortality Associated with Atypical and Typical Antipsychotics in Demented Outpatients: A Population-Based Study [1475]
Gianluca Trifò, Kata MC Verhamme, Gijsbertus Ziere, Achille P Caputi, Bruno HCH Stricker, Miriam CJM Sturkenboom. (Italy)

2 Fatal Reports in Intramuscular vs Oral Antipsychotics in the FDA Adverse Event Reporting System (AERS) [1476]
Sebastian Sorsaburu, Karen E Chilcott, F Patrick DeLisa; Kenneth Hornbuckle. (United States)

3 Has the Warning Issued in 2003 on Increased Risk of Suicide Associated with SSRI Use Had an Impact on Current Antidepressant Users? [1477]
Louise Barnard. (Canada)

4 Venous Thromboembolism during Treatment with Antipsychotics [1478]
Olav Spigset, Andrew Bate, Malin Ståhl, Staffan Hägg. (Norway)

5 Identification of Patients with Rheumatoid Arthritis Using Drug Database Data [1479]
Marie-Agnes Bernard, Patrick Blin, Bernard Begaud, Abdelilah Abouelfath, Nicholas Moore, Annie Fourrier. The CADEUS Study Team. (France)

6 Efficiency and Relative Power of Nested Case-Control Studies [1480]
Alex D McMahon. (United Kingdom)

7 A Comparison of Two Multiple Characteristics Decision Making Techniques for the Comparison of Antihypertensive Drugs: Simple Additive Weighting and Technique for Order Preference by Similarity to an Ideal Solution [1481]
Boris LG Van Wijk, Olaf K Blung, Eibert AP Pols, Bruno HCH Stricker. (Netherlands)

8 Methodologic Lessons Learned in a Cluster-Randomized Trial of an Intervention to Improve Hypertension Control [1482]

9 Risk-Benefit Analysis of Rofecoxib Versus Naproxen for the Treatment of Rheumatoid Arthritis Patients: A Discrete Event Simulation [1483]
Larry D Lynd, Carlo A Marra, Mehdi Najafzadeh, Mohsen Sadatsafavi. (Canada)

10 Use of Selective Serotonin Inhibitors and Risk of Hip/Femur Fractures: A Population-Based Case-Control Study [1484]
Brahm Tho, Frank de Vries, Antoine CG Egberts, Bert GM Leufkens, Tjeerd P van Staaij. (Netherlands)

11 Long-Term Use of Selective Serotonin Reuptake Inhibitor Antidepressants Is Associated with Increased Risk of Non-Vertebral Fractures [1485]
Gijsbertus Ziere, Jeanne P Dieleman, Tischa JM van der Cammen, Albert Hofman, Huibert AP Pols. (Netherlands)

12 Meta-Analysis of Adverse Effects in Placebo Controlled Studies with Paroxetine [1487]
Ivar Aurnes. (Norway)

13 Comparison of Hospital Readmission Rates in Patients with Acute Myocardial Infarction Stratified by Antidepressant Use [1488]
Christopher M Blanchette, Stephen Stemkowski, Christopher Craver, William B Saunders. (United States)

14 Effects of Fluvoxamine, Fluoxetine and Placebo on Psychomotor Performance in Healthy Volunteers [1489]
Emmanuel Ponciano, Margarida Pocinho, Elisabete Mota, Helena Monteiro, Ian Indmarch. (Portugal)

15 Prescribing of Tricyclic Antidepressants and Selective Serotonin Re-Uptake Inhibitors in Children and Adolescents in South Africa [1490]
Kristen Van Schalkwyk, Ilse Truter. (South Africa)

16 Behavioural Toxicity of Mianserin and Fluoxetine [1491]
Helena Jardim, Emanuel Ponciano, Ian Hindmarch. (Portugal)

17 Revisited Effects on Psychomotor Functions of Clobazam and Diazepam – A Double-Blind Study [1492]
Helena Jardim, Emanuel Ponciano, Ian Hindmarch. (Portugal)

18 Differences in Benzodiazepine Prescribing in South Africa between 1996 and 2004 [1493]
Ilse Truter, Theunis JAW Kotze. (South Africa)

19 Outpatient Utilization of Benzodiazepines in Croatia 2001–2004: Comparison with Scandinavian Countries [1494]
Daniela Stimaq, Josip Culg, Ivan Vukusic, Zvonimir Sostar, Sinisa Tomic. (Croatia)

20 Validation of ICD9–Codes for Upper Gastrointestinal Bleeding in the Saskatchewan Health Databases [1496]
V Gimeno, M Bernat, MR Stang, J Aquado, J Castellsague, S Perez-Guthmann. (Spain)

21 Validity of Hospital Discharge ICD Codes for Identifying Patients with Thrombocytopenia [1497]
Maarten J ten Berg, Albert Huisman, Patricia MLA van den Bernt, Alfred FAM Scholten, Antoine CG Egberts, Wouter W van Solinge. (Netherlands)

22 Contribution of the Different Medical Record Sources to the Drug Use Information: Analysis Using the Rochester Epidemiology Project (REP) Integrated Medical Record System [1498]
Paulo J Nicola, Hilal Maradit-Kremers, Megan S Reinalda, Cynthia S Crowson, Sherine E Gabriel. (United States)

23 Estimating Period Prevalence Using Censored Data [1499]
John W Logie, Maurille A Feudjo-Tepie. (United Kingdom)

24 Development and Validation of Database Measures of Asthma Severity and Control [5001]
Farahak Firoozi, Catherine Lemiere, Marie-France Beauchesne, Amelie Forget, Lucie Blais. (Canada)

25 Validation Studies of the Health Improvement Network (THIN) Database for Pharmacoepidemiology Research [5002]
James D Lewis, Rita Schinnar, Warren B Bilker, Xingmei Wang, Brian L Strom. (United States)

26 Quality Assurance Analyses of Data from Five Large US Medicaid Programs [502]
Sean Hennessy, Charles E Leonard, Craig Newcomb, Warren B Bilker. (United States)
29 Does the Generic Formulation of the beta-Blocker Metropolol Carry a Higher Risk for Hospitalization Than the Originator? [5031]
Wolfgang Ahrens, Bernd Muehlbauer, Juergen Timm, Iris Pigeot. (Germany)

30 Angiotsensin II Receptor Blockers (ARB), Hypertensive Treatments, and the Risk of Myocardial Infarction: A Systematic Review of the Literature [5041]
Matthew W Reynolds, Brian Sercus, Janet Claflin, Allen Feldman. (United States)

31 Effects of Antihypertensive Drug Treatments on Fracture Outcomes: A Meta-Analysis of Observational Studies [5051]
Matthew Wiens, Mahyar Etminan, Sudeep Gill, Bahi Tahkouche. (Canada)

32 Erectile Dysfunction in Males Treated with Antihypertensive Drugs. A Review of Spontaneous Reports in the Swedish and WHO Adverse Drug Reaction Databases [5061]
Elisabet Ekman, Viktoria Werkstrom, Petter Hedlund. (Sweden)

33 Effect of Concomitantly Used CYP-3A4 Inhibitors in Patients Treated with Calcium Channel Blockers [5071]
Takeshi Mayama, Toshiyuki Fujita, Masanori Yoshida, Takayuki Matsumoto. (Japan)

34 Incidence of Diabetes in Users of Antipsychotics in Australia [5081]
Richard L Hill, Ian W Boyd, Lisa J Calcino, Robert L Walsh, Judy Zhang. (Australia)

35 Prescribing Patterns in Chronic Psychiatric Patients [5091]
Susanne G Schorr, Anton JM Looen, Jacobus RJ Brouwers, Katja Taxis. (Netherlands)

36 Pain Management in Patients under Opiate Maintenance Treatment [5091]
Maryline Desplas, Anne Roussin, Maryse Lapeyre-Mestre. (France)

37 Use of Antidepressants in an Urban Sample of Portuguese Adults [5111]
Joana Bastos, Raquel Lucas, Ana Azevedo, Henrique Barros. (Portugal)

38 Drug Diversion in Community Pharmacies in France: Profiles of Suspect Prescriptions Observed in the National Survey OSIAP (Ordonnances Suspectes Indicateur d'Abus et de Pharmacodependance) 2001-2004 [5121]
Olivia Bœuf, Maryse Lapeyre-Mestre. French Network of CEIP. (France)

39 Patient Reports on Discontinuation of Antidepressants [5131]
Katja van Geffen, Rolf van Hulten, Marcel Bouvy, Eibert R Heerdink, Antoine CG Egberts. (Netherlands)

40 The Risk of Ischemic Stroke Associated with COX-2 Selective NSAID Use – A Nested Case Control Study [5141]
Frank Anderssohn, René Schade, Samy Suissa, Edelrout Gabe. (Germany)

41 Serious Skin Reactions and COX-2 Inhibitors: A Case Series from Prescription-Event Monitoring (PEM) in England [5151]
Deborah Layton, Vanessa Marshall, Andrew Boshier, Peter Friedmann, Saad Shakir. (United Kingdom)

42 Acetaminophen and Non-Steroidal Anti-Inflammatory Drug Use and Risk of Incident Hypertension in Apparently Healthy Women [5161]
Tobias Kurth, Julie E Buring, J Michael Gaziano. (United States)

43 Factors Associated with Gastroprotective Agent Usage Pattern in NSAIDs Users: A Multinomial Analysis in the CADEUS Study [5171]
Regis Lassalle, Jacques Berichou, Fanny Depont, Nicholas Moore, Cecile Droz, Michel Amouretti, Patrick Blin, Annie Fourrier, The CADEUS Study Team. (France)

44 Did the Withdrawal of Rofecoxib Impact on Prescribing Trends of Non-Steroidal Anti Inflammatory / Analgesic Drugs? [5181]
Kathleen Bennett, Mary Teeling, John Feely. (Ireland)

45 NSAID Use Is Associated with Lower Mammographic Breast Density in Younger Women [5191]
Tamarra James, Mary Beth Terry, Amy Trentham-Dietz, Diana SM Buist. (United States)

46 Risk of Lung Cancer among Users of Non-Steroidal Anti-Inflammatory Drugs [5201]
Sonia Hernández-Díaz, Luis A García Rodriguez. (United States)

47 Quantitative Assessment of the Gastrointestinal and Cardiovascular Risk-Benefit of Celecoxib Compared to Individual NSAIDs at the Population Level [5211]
CVaras-Lorenzo, A Maguire, J Castellsague, S Perez-Gutthann. (Spain)

48 Use of Selective COX-2-Inhibitors in Norway before and after the Withdrawal of Rofecoxib – Norwegian Prescription Database [5221]
Kari Furu, Svetlana Skurtvet, Lars Skårdal. (Norway)

49 Who Were the New COX-2 Users in CADEUS? [5231]
Cecile Droz, Nicholas Moore, Fanny Depont, Michel Amouretti, Patrick Blin, Annie Fourrier. The CADEUS Study Team. (France)

51 Prescribing Patterns of Anti-Migraine Drugs in a Primary Care Patient Population [5251]
Ilse Truter. (South Africa)

52 Exploring the Use of Analgesics and Nutritional Supplements by Patients with Knee Pain [5261]
Garry R Barton, Anthony J Avery, Tracey H Sach, Claire Jenkinson, Kenneth R Muir. (United Kingdom)

53 Pain Management Pattern on Cancer Patients [5271]
Hwa J Kim, Nam-kyong Choi, Sun-young Jung, Joo-young Kim. Byung-Joo Park. (Korea)

54 Statins and the Risk of Lung, Breast and Colorectal Cancer [5281]
Soko Setoguchi, Robert J Glynn, Jerry Avorn, Helen Mogun, Sebastian Schneeweiss. (United States)

55 Impact of Statin Adherence on Non Fatal Coronary Artery Disease (CAD) among Patients for Primary Prevention [5291]
Sylvie Perreault, Alice Dragomir, Lucie Biais, Lyne Lalonde, Anick Bérard, Michel White. (Canada)

56 Impact of Statin Adherence on Non Fatal Stroke among Patients for Primary Prevention [5301]
Sylvie Perreault, Alice Dragomir, Lucie Biais, Lyne Lalonde, Anick Bérard, Robert Côté. (Canada)
57 Acute Effects of Discontinuation of Statin Treatment on the Occurrence of a First Myocardial Infarction [531]
Auke K Mantel-Teeuwisse, Menno E van der Elst, Olaf H Klabung, Marcel L Bouvy, Cornelis J de Blaey, Anthonius de Boer. (Netherlands)

58 Rosuvastatin’s Safety Profile Is Comparable to That of Other Marketed Statins: Results from a Historical Cohort Study in More Than 45,000 Dutch Statin Users [532]
Wim G Goetsch, Edith Heintjes, John JP Kastelein, Saga Johansson, Ron MC Herings. (Netherlands)

59 Adherence to Statin Therapy in Patients Who Persist with Treatment [533]
Thomas I Barron, Kathleen Bennett, John Feely. (Ireland)

60 Role of Medication in Patient’s Revisits at the Montreal Heart Institute Emergency Department [534]
Vincent Raymond, Alain Vadeboncoeur, Wendy Kennedy, Claudine Laurier. (Canada)

61 Prescribing of Statins in Norway after New Reimbursement Regulations in 2005 – Data from the Norwegian Prescription Database (NorPD) [535]
Solveig Sakshaug, Kari Furu, Svetlana Skurtveit, Marit Rønning. (NorPD) [536]

62 High Dose Statin Prescribing after the PROVE-IT, REVERSAL and TNT Studies [536]
Thomas I Barron, Kathleen Bennett, John Feely. (Ireland)

63 Incidence of Severe Myositis in Patients Treated with Lipid-Lowering Drugs [537]
Ju Young Kim, Byung Joo Park. (Republic of Korea)

64 Interrelation between Antihypertensive Medication Use and CVD Lifestyle Risk Factor Modification [538]
C Ineke Neutel, Norm RC Campbell. (Canada)

65 Hypercholesterolemia and Hypertension Management in Type 2 Diabetes Patients between 1998–2003: Longitudinal Observational Study [539]
Johanna P Crivign, Petra Demig, Dick de Zeeuw, Henk JG Bilo, Flora M Haaijer-Ruskamp. (Netherlands)

Nitesh K Choudhry, Jeffrey Avorn, Sebastian Schneeweiss. William H Shrank. (United States)

67 Population-Based Study: Adherence Level of Antihypertensive Agents (AH) on Non Fatal Strokes [541]
Sylvie Perreault, Alice Dragoner, Lucie Blais, Lynne Lalonde, Anick Bénard, Robert Côté. (Canada)

68 Statin Prescribing in British Columbia, Canada [542]
Colette B Raymond, Steven G Morgan, Patricia A Caetano. (Canada)

69 Adherence to Chronic Cardiovascular Therapies: Persistence over the Years and Dose Coverage [543]
Elisabetta Poluzzi, Petar Srafinjina, Antonio Vargiu, Maria Chiara Silvani, Domenico Motola, Alberto Vaccheri, Fabrizio De Ponti, Giulio Marchesini Reggiani, Nicola Montanaro. (Italy)

70 Lipid Lowering Therapy in the Prevention of Age Related Macular Degeneration: A Meta-Analysis of Observational Studies [544]
Matthew Wiens, Jean Chuo, David Maberly, Mahyar Etminan. (Canada)

71 Population-Based Study: Adherence Level of Antihypertensive Agents (AH) on Coronary Artery Disease (CAD) [545]
Sylvie Perreault, Alice Dragoner, Lucie Blais, Lynne Lalonde, Anick Bénard, Michel White. (Canada)

72 10 Year Coronary Artery Disease Risk (RCAD) Reduction after Treatment with Ezetimibe 10mg/Day Co-Administered with Statins in Patients with Primary Hypercholesterolemia That Have Not Reached Target LDL-C Levels While on Statin Monotherapy [546]
Stéphane Bissonnette, Rafik Habib, Stella Boukas, John Sampalis. (Canada)

73 Cardiovascular Drug Utilization in Portugal (2000–2004) [547]
Claudia Furtado, Ines Teixeira. (Portugal)

74 Persistence with Statin Therapy in British Columbia, Canada [548]
Colette B Raymond, Patricia Caetano, Steve Morgan, Anita Kozyrskyj, Alan Katz. (Canada)

75 Prevalence, Awareness, Treatment and Control of Hypertension in the Portuguese General Population [549]
Ana Azevedo, Raquel Lucas, Henrique Barros. (Portugal)

76 Adherence to EPA Was Important in Receiving the Clinical Benefit for Hypercholesterolemia [550]
Hideki Origasa, Masanori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Mitsuhiro Yokoyama. (Japan)

77 Comparison of Statin Use in Three Norwegian Counties in 2004 – An Individualised Prescription Database Study [551]
Ingeborg Hartz, Sakshaug Solveig, Furu Kari, Engeland Anders, Eggen E Anne, Njalstad Inger, Skurtveit Svetlana. (Norway)

78 Consumption of Statins in the Republic of Tatarstan (Russia) [552]
Lilia E Ziganshina, Eugenya A Arsel, Lilia N Muhamadullina, Albert S Galyavich. (Russian Federation)

79 Higher Persistence with Valsartan Compared to Enalapril in Daily Practice [553]
Satu J Siskonen, Nancy S Breekveldt-Postma, Gábor Vince, Zeba M Khan, Joëlle A Erkens, Ron MC Herings. (Netherlands)

80 A Potential Protective Effect of Topical Calcineurin Inhibitors with Respect to Non Melanoma Skin Cancer [554]
David J Margolis, Ole Hofstad, Warren Bilkner. (United States)

81 Cardiovascular Risk Factors and Occurrence of Cardiovascular Adverse Events in Patients with Advanced Breast Cancer Receiving Chemotherapy [555]
Nancy N Breekveldt-Postma, Myrthe PP Sukel, Joëlle A Erkens, Paul D van der Linden, Annette B Bederbeek, Ron MC Herings. (Netherlands)

82 Bone Metastatic Disease from Breast Cancer – Treatment with Bisphosphonates in Czech Republic Versus International Guidelines [556]
Veronika Yokata, Ales Kubena, Jiri Vlcek. (Czech Republic)

83 Cancer Risks Associated with Antidiabetic Agents [557]
Carol E Koro, Steven J Barrett, Nawab Qizilbash. (United States)
<table>
<thead>
<tr>
<th>Session C</th>
<th>Sunday, August 27</th>
</tr>
</thead>
<tbody>
<tr>
<td>84 Study of Survival and Estimated Prevalence of Cancer of the Renal Parenchyma in France</td>
<td><a href="#">558</a></td>
</tr>
<tr>
<td>Arlette Danzon, Carolle Langlois, Pascale Grosclaude, Marc Colonna, Patricia Delafosse, E Martin, Florence Molinie, Brigite Tretarre, Michel Velten, Fleur Levrat. (France)</td>
<td></td>
</tr>
<tr>
<td>85 Incidence in 2000 of Cancer of the Renal Parenchyma in France</td>
<td><a href="#">559</a></td>
</tr>
<tr>
<td>Arlette Danzon, Carolle Langlois, Pascale Grosclaude, Michel Velten, Brigite Tretarre, Florence Molinie, E Martin, Patricia Delafosse, Marc Colonna, Fleur Levrat. (France)</td>
<td></td>
</tr>
<tr>
<td>86 Upgraded to Oral Presentation</td>
<td><a href="#">560</a></td>
</tr>
<tr>
<td>87 Antipsychotic Treatment Discontinuation in the Outpatient Treatment for Schizophrenia: French Results from the Pan European Soho Study</td>
<td><a href="#">561</a></td>
</tr>
<tr>
<td>Isabelle Gasquet, Stephanie Tcherny-Lessenot, Florence Chartier, Jean-Pierre Lepine. (France)</td>
<td></td>
</tr>
<tr>
<td>88 Isotretinoin and the Risk of Depression in Patients with Acne: A Case-Crossover Study</td>
<td><a href="#">562</a></td>
</tr>
<tr>
<td>Laurent Azoulay, Lucie Bias, Anick Berard. (Canada)</td>
<td></td>
</tr>
<tr>
<td>89 A Case Series of Progressive Multifocal Leukencephalopathy in an Insured Population</td>
<td><a href="#">563</a></td>
</tr>
<tr>
<td>P Mona Eng, Bruce R Turnbull, Suzanne F Cook, Julie E Davidson, Tobias Kurth, John D Seeger. (United States)</td>
<td></td>
</tr>
<tr>
<td>90 Epidemiology and Treatment of Neuropathic Pain in Primary Care</td>
<td><a href="#">564</a></td>
</tr>
<tr>
<td>Jeanne P Dieleman, Joost Kerklaan, Daan Caudri, Vincent Schoites, Miriam C Sturkenboom. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>91 Do COX-2 Inhibitors Prevent Deterioration of Schizophrenia? A Nested Case-Control Study</td>
<td><a href="#">565</a></td>
</tr>
<tr>
<td>Pieter Stolk, Patrick C Souverein, Iain D Tatt, Antoine CG Egberts, Hubert GM Leufkens, John G Weil, Eibert R Heerdink. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>92 Cerebral Symptoms after Treatment with Isotretinoin</td>
<td><a href="#">566</a></td>
</tr>
<tr>
<td>B Werner, I Buajordet, S Madsen. (Norway)</td>
<td></td>
</tr>
<tr>
<td>93 The Incidence of Diagnosed Progressive Multifocal Leukencephalopathy (PML) in the General Insured Population, an Insured Cohort with Multiple Sclerosis (MS) and an Insured Cohort with Crohns Disease (CD)</td>
<td><a href="#">567</a></td>
</tr>
<tr>
<td>Adam T Linke, Chanchal Bains, David J Webb, Suzanne F Cook, LUIS C Sanin, Julie E Davidson. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>94 Comparing Insulins: People Using Human Insulin Are the Least Likely to Switch</td>
<td><a href="#">568</a></td>
</tr>
<tr>
<td>Annie Hutchison, David Russel-Jones, Corinne S de Vries. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>95 Comparing Insulins: No Difference in Likelihood of Serious Adverse Events in Type II Diabetes after Starting on Animal, Human or Analogue Insulin</td>
<td><a href="#">569</a></td>
</tr>
<tr>
<td>Annie Hutchison, David Russel-Jones, Corinne S de Vries. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>96 Rates and Risks of Starting Insulin in Diabetes Mellitus Type 2 Patients</td>
<td><a href="#">570</a></td>
</tr>
<tr>
<td>Miriam C Sturkenboom, Jeannie P Dieleman, Johan van der Lei. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>97 Introduction of COX-2 Inhibitors Did Not Change Hospitalization Rates of Bleeding and Perforated Peptic Ulcer in Denmark</td>
<td><a href="#">571</a></td>
</tr>
<tr>
<td>Steffen Christensen, Mette Norgaard, Anders Riss Riss, Reimar W Thomsen, Henrik T Sorensen. (Denmark)</td>
<td></td>
</tr>
<tr>
<td>98 Hepatitis Associated with Herbal Preparations</td>
<td><a href="#">572</a></td>
</tr>
<tr>
<td>Francesca Menniti-Ippolito, Carmela Santuccio, Fabio Frenzuoli, Gabriela Mazzanti, Paola Moro, Andrea Valeri, Roberto Raschetti. (Italy)</td>
<td></td>
</tr>
<tr>
<td>99 Tegaserod Is Modestly Effective but Safe for Treatment of Irritable Bowel Syndrome or Chronic Constipation: A Meta-Analysis of Randomized Trials</td>
<td><a href="#">573</a></td>
</tr>
<tr>
<td>Janet Martin, Marc Bardou. (France)</td>
<td></td>
</tr>
<tr>
<td>100 The Impact of Cancer on the Short Term Outcome of Oral Glucocorticoid Use after Peptic Ulcer Bleeding</td>
<td><a href="#">574</a></td>
</tr>
<tr>
<td>Marianne Rhode, Anders Riss, Steffen Chrisstensen, Mette Norgaard, Reimar W Thomsen, Henrik T Sorensen. (Denmark)</td>
<td></td>
</tr>
<tr>
<td>101 NSAIDs and the Risk of Upper Gastro-Intestinal Events: A Nested Case-Control Study</td>
<td><a href="#">575</a></td>
</tr>
<tr>
<td>Katia MC Verhamme, Georgio Mosis, Jeanne P Dieleman, Johan van der Lei, Bruno HC Stricker, Miriam CJM Sturkenboom. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>102 Persistence and Adherence to Proton Pump Inhibitors in Daily Clinical Practice</td>
<td><a href="#">576</a></td>
</tr>
<tr>
<td>Eva M van Soest, Peter D Siersema, Jeanne P Dieleman, Miriam CJM Sturkenboom, Ernst J Kuipers. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>103 Incidence and Risk Factors for Intestinal Ischemia</td>
<td><a href="#">577</a></td>
</tr>
<tr>
<td>Consuelo Huerta, Miguel A Montoro, Belen Sanchez, Elena Rivero, Fabio Levano, Luis A Garcia-Rodriguez. (Spain)</td>
<td></td>
</tr>
<tr>
<td>104 Quality of Pharmacist-Managed Anticoagulation Service: A Randomized Controlled Trial</td>
<td><a href="#">578</a></td>
</tr>
<tr>
<td>Lyne Lalonde, Josee Martineau, Normand Blais, Martine Fournier, Djamel Berbiche, Marie-Claude Vanier, Lucie Blais, Sylvie Perreault, Isabel Rodrigues, Martine Montigny, Jeffrey Ginsberg. (Canada)</td>
<td></td>
</tr>
<tr>
<td>105 Abstract Withdrawn</td>
<td><a href="#">579</a></td>
</tr>
<tr>
<td>106 Range Restriction May Reduce Bias in Stratified Propensity Score Analyses: Simulation Results Based on Uniform Effects</td>
<td><a href="#">580</a></td>
</tr>
<tr>
<td>Til Stürmer, Sebastian Schneweiß, Kenneth J Rothman, Jerry Avorn, Robert J Glynn. (United States)</td>
<td></td>
</tr>
<tr>
<td>107 Projections of the Prevalence of Chronic Myelogenous Leukaemia in the EU: Impact on Its Orphan Status</td>
<td><a href="#">581</a></td>
</tr>
<tr>
<td>Katarzyna Sablinska, Carles Blanch, Ana Rueda. (United States)</td>
<td></td>
</tr>
<tr>
<td>108 Incidence of Myocardial Infarction and Cerebrovascular Accidents in Patients with Wet Age-Related Macular Degeneration in a Commercially Insured Population</td>
<td><a href="#">582</a></td>
</tr>
<tr>
<td>Earl Goehring, Jr., Bao-Anh Nguyen-Khoa, Winfred Werther, Pavel Napalkov, Judith K Jones. (United States)</td>
<td></td>
</tr>
<tr>
<td>109 A Study of the Association between Hypothyroidism and Open-Angle Glaucoma in an Elderly Population</td>
<td><a href="#">583</a></td>
</tr>
<tr>
<td>Stephen P Motsko, Judith K Jones. (United States)</td>
<td></td>
</tr>
</tbody>
</table>
110 Blood Pressure Lowering Thresholds and Stroke 15841
Nawal Qzilbash, Adrian Mander, Maurille Feudjo-Teppe, Nada Boudiaf. (United Kingdom)

111 Incidence Rates of Hospitalization-Associated Bone Fractures in Dialysis Patients in the United States Renal Data System 15851
Victor Castanaga, Sean Zhao, Nina Stuccio-White, Atsuko Shibata. (United States)

112 Cardiovascular Outcomes in a Large Cohort of Patients with Treated Hypertension: A Demonstration Study 15861
Andrew T McAfee, Joan Landon, DONNIE Funch, Miguel Gil, Carles Blanch, Alexander M Walker. (United States)

113 Comorbidity Influence in COPD: Attributable Mortality Risks 15871
Victor A Kim, James Oyee. (United Kingdom)

114 Global Cardiovascular Risk Screening - A Community Pharmacy Based Study 15881
SO Martins, J Cabrita, M Caramona, J Vanmil. (Portugal)

115 The Incidence of Microvascular and Macrovacular Complications in Koreans with Type 2 Diabetes: REKORD Study 15891
Yooni Kim, Dong-Seop Choi, Byung-Joo Park, Myung-Joo Byun, YL-Seob Lee, REKORD Study Group. (Korea)

116 Do Non Responders Differ from Responders in a Mailed Questionnaire among Users of Inhaled Corticosteroids? 15901
Tanja T Mengecberg, Marcel L Bouvy, Madelon Bracke, Martine Koppelaar, Jan A Raaijmakers, Hubert GM Leufkens. (Netherlands)

117 Small Area Prevalence of Diabetes and Hypertension Estimated from the Portuguese National Health Survey Using Bayesian Hierarchical Modelling 15911
Valencio Andreozzi, Jorge Felix, Pedro Saramago. (Portugal)

118 Risk of Cerebrovascular Event among Patients Newly Diagnosed with Atrial Fibrillation 15921
Ana Ruizgomez, Saga Johansson, MarHann Wallander, Luis-Alberto Garcia-Rodriguez. (Spain)

119 Incidence and Natural History of Psoriasis Diagnosed in General Practice 15931
Consuelo Huerta, Elena Rivero, Miguel Gil, Luis-Alberto Garcia-Rodriguez. (Spain)

120 Knowledge, Attitudes, and Preventive Behaviors for Tuberculosis by Thailand Hospital Healthcare Workers 15941
Saisonee Baramee, Anongpon Prapanwong, Siriyong Tipsiriraj, Made-ta Kam-in, Penkarn Kanjanarat. (Thailand)

121 DDD as a Measure of Disease Prevalence: Possible Pitfalls 15951
Marc De Falleur, Johan De Haes, André De Swae. (Belgium)

122 Macular Degeneration and Mortality in NHANES III Participants 15961
Bao-Anh Nguyen-Khoa, Earl Goehring, Jr., Winfred Werther, Pavel Napalkov, Judith K Jones. (United States)

123 Prevalence of Common Diseases in the Rural Areas of the Eastern Cape, South Africa as Observed by Phelophepa 15971
Ilse Truter, Hlabishi F Mohlala, Danie JL Venter. (South Africa)

124 Prevalence of Obesity in Portugal 15981
Carla P Santos, Mario E Macedo, Catarina P Silva. (Portugal)

125 Design and Implementation of the Transhyretin Amyloidosis Cardiac Study (TRACS) To Examine the Natural History of Familial Amyloid Cardiomyopathy (FAC) 15991
Matthew W Reynolds, Heather Linz, Sheila Cream, Kunsten Tcholgor, Jeff Packman, Rodney Falk, Fredrick Ruberg. (United States)

126 The Use of Nonlinear Functions To Incorporate Clinical Trial Data into Cost-Effectiveness Analysis: Cabergoline vs Bromocriptine in Hyperprolactinaemia 16001
Mónica Inês, Jorge Félix, Catia Acosta. (Portugal)

127 The Impact of Rimonabant on Obesity-Related Diseases and Quality of Life: A Cost-Utility Analysis 16011
Christian Hampp, Abraham C Hartzema. (United States)

128 Impact of Electronic Prescribing on Use of Generic Medications 16021
Michael A Fischer, Christine Vogeli, Margaret Sedman, Rainu Kaushal, Timothy Ferris, Joel S Weissman. (United States)

129 A Simple Model for Calculating the Incidence of Rare Tumours in Other Countries – An Example Using the Incidence of Glioblastoma Multiforme in the United Kingdom 16031
Simon Voss, Vivian Mak, Steve George, Kenneth Hornbuckle. (United Kingdom)

130 Factors Associated with Spending on Inappropriate Medicines among Elderly People in Belo Horizonte, Brazil 16041
Marina C Lima, Andrea Q Ribeiro, Francisco A Acucico, Susel Rozenfeld, Carlos H Klein. (Brazil)

131 Pharmacoepidemiological Aspects of Reforms of Pharmaceutical Part of Republic Health Financial Service in Montenegro Republic 16051
Zdenko Tomic, Ana Sabo, Momir Mikov, Rano Bralic, Zoran Gomazic, Vaja Lazoric. (Yugoslavia)

132 HMG-CoA Reductase Inhibitors and Fracture Risk – A Meta-Analysis 16061
Sengwee Toh, Sonia Hernández-Diaz. (United States)

133 Incident Hematologic Malignancies and Solid Tumors and Their Date of Diagnosis Can Be Identified with High Specificity in Medicare Claims Data 16071
Soko Setoguchi, Daniel H Solomon, Robert J Glynn, E Francis Cook, Sebastian Schneeweiss. (United States)

134 Prescriber Non-Participation in the CADEUS Study Did Not Induce Patient Selection Bias 16081
Fanny Depont, Nicholas Moore, Cecile Droz, Michel Amouretti. (France)

135 Measuring Treatment Adherence Using the DDD Concept 16091
Frank Meyer, Gerd Glaeske. (Germany)

136 Accuracy of Recall of Recent Medication Use 16101
Carol Louik, Judith P Kelly, David W Kaufman, Theresa Anderson, Lynn Rosenberg, Allen A Mitchell. (United States)
137 Use of the Electronic Medical Records (EMR) for Safety Surveillance: Biologies as an Example [611]
Hiall Maradit Kremers, Sergei V Pakhomov, Cynthia D Crowson, Nilay D Shah, Sherine E Gabriel. (United States)

138 Potential Bias Due to Selection of Controls in Secondary Data Analysis: Nonaspirin Nonsteroidal Anti-Inflammatory Drugs (NANSAIDs) and Hemorrhagic Stroke [612]
Nam-Kyong Cho, Seokyung Hahn, Seung-Mi Lee, Byung-Joo Park, Byung-Woo Yoon. (Korea)

139 Validity of a Modified PUQE Scoring Index To Assess Severity of Nausea and Vomiting of Pregnancy (NVP); Effect of Antiemetic Utilisation [613]
Anais Lacasse, Evelyne Re, Ema Ferreirra, Caroline Morin, Anick Berard. (Canada)

140 Hungarian Hospital Antibiotic Consumption. Does It Matter Which Measure? [614]
Ria Benko, Maria Matuz, Peter Doro, Reka Viola, Edit Hajdu, Gyongyver Soos. (Hungary)

141 The Development of the Quantitative Instrument for Assessing the Quality of Clinical Trial Reports [615]
Peishan Wang, Dengyuan Zhou, Zhenlin Jia, Lijian Li, Jiang Tian. (China)

142 Does Where You Distributed Impact What You Get? The Role of Distribution Method on Response Rates and Positivity Bias in a Patient Safety Questionnaire in Nursing Homes [616]
Kate L Lapane, Brian J Quilliam, Carnel M Homes. (Canada)

143 Making a Curriculum Vita Numerical and Graphical for Tenure, Promotion and Career Awards [617]
Charlie H Goldsmith. (Canada)

144 Iressa and Interstitial Lung Disease (ILD) in Japan – Lessons from a Large Nested Case-Control Study To Evaluate a Safety Issue [618]
Fredrik Nyberg, Shiju Hada, Kenneth J Rothman, The Iressa CCS Collaborator Group. (Sweden)

145 Methotrexaate: Patient Knowledge of Key Safety Issues [619]
Anthony R Cox, Carol Higham, Michelle L Chandler, R D Situnayake. (United Kingdom)

146 Prevention of Chemotherapy Related Errors – One Step Toward [620]
Catarina Oliveira, Filipa Duarte-Ramos, José Cabrita. (Portugal)

147 Concomitant Prescribing Rates of Statins and Cytochrome P450 3A4 Inhibitors and Inducers in Real-World Clinical Practice [621]
Michael H Davidson, Sanjay K Gandhi, Eileen E Ming, Xiongkan Ke, Pollack S Pia, Marcelo A Marotti, McKenney M James. (United States)

148 Safety Profile of Rosuvastatin as Used in General Practice in England: A Prescription-Event Monitoring Study [622]
Rachna Kasliwal, Lynda Wilton, Saad Shaker. (United Kingdom)

149 Mass Media Reporting of Cancer Drug Risks [623]
Jessica M Fishman. (United States)

150 Risk Management in Dyslipidemic Patients in a Portuguese Community Pharmacy [624]
Claudia A Pereira, Joaquim Cabrita. (Portugal)

151 Risk-Benefit Assessment of Drug Interventions Using Multicriteria Decision Modeling [625]
Rebecca A Noel, James C Felli, Patrizia Cavazzoni. (United States)

152 Determinants of Drug-Information Needs during Consultation Hours [626]
Anuschka S Niemeijer, Jan Schuling, Flora M Haaijer-Ruskamp, (Netherlands)

153 The Use of Thalidomide as Unapproved Drug: Time Trend and the Impact of the Clinical Guideline in Japan [627]
Hikaru Watanabe, Eri Kawabe, Nobuhiro Ooba, Tsugumichi Sato, Yong Sa Lim, Kiyoshi Kubota. (Japan)

154 Managing Therapeutic Risk in Portuguese Community Pharmacies: A Feasibility Study [628]
Mara P Guerreiro, Judhith A Cantrill, Ana P Martins. (United Kingdom)

155 Herbal and Dietary Supplement Use in Older American Women [629]
C W Shinoff, L Chang, L Lui, F Modugno, D C Bauer. (United States)

156 Adherence with Proton Pump Inhibitors and Non-Selective NSAIDs and Impact on Gastrointestinal Hospitalizations [630]
Spyrius van der Bij, Nancy Breekveldt-Postma, Wim G Goettsch, Corinne Chen, Joelle Erkens, Ron MC Herings. (Netherlands)

157 Adherence to Evidence-Based Statin Guidelines Reduces Risk for Acute Myocardial Infarction by 40% [631]
Fernie JA Penning-van Beest, Wim G Goettsch, Olaf H Klungel, John JP Kastelein, Ron MC Herings. (Netherlands)

158 The Effect of Nonsteroidal Anti-Inflammatory Drugs on the Therapy of Antihypertensive Drugs [632]
Chieko Ishiguro, Toshiharu Fujita, Takeshi Mayama, Takashi Omori, Toshiya Sato. (Japan)

159 Compliance with Bisphosphonate Therapy Reduces Risk of Osteoporotic Fracture by 25-30% in Post-Menopausal Women [633]
Fernie JA Penning-van Beest, Christel HA van den Boogaard, Joelle A Erkens, Astrid MT Engbersen, Ron MC Herings. (Netherlands)

160 Adherence to Clinical Guidelines in Empiric Antibiotics Choice and Its Influence on Outcomes of Community-Acquired Pneumonia in Hospitalized Belarussian Patients [634]
Maxim N Mily, Marina M Sachek, Vladimir Y Lugovoy, Gennady G Voronov. (Belarus)

161 Post-Marketing Surveillance Study for the Efficacy and Safety of Vardenafil among Patients with Erectile Dysfunction in Primary Care [635]
Young-Sik Kim, Chul-Min Kim, Sung Sunwoo. (Korea)

162 Effect of Academic Detailing on Antibiotic Prescribing among General Practitioners (GPs) [636]
Corina Naughton, Kathleen Bennett, John Feely. (Ireland)

163 Infant Mortality Rates Reduction with Haemophilus Influenzae Vaccination in Colombia [637]
Fernando Guerrero, Diego Arboleda. (Colombia)

164 Self-Reported Compliance with Antiresorptive Treatment [638]
Magda Vyttsralova, Sarka Blazkova, Jiri Vlcek. (Czech Republic)
165 Anticonvulsants’ Use in Adolescents [639]
Rimma G Gamirova, Svetlana N Sivkova, Fanya M Zaikova, Lilia E Ziganshina. (Russian Federation)

166 Effects on Asthma Mortality Rates in Italy after the Introduction of Long Acting b2-Agonists (LABAs) [640]
Francesco Bamfi, Matteo Dionisi, Gabriele Lazzeri. (Italy)

167 Utilization of Central Nervous System Stimulants (CNSs) in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD): A Study of Florida Medicaid Beneficiaries 1994-2004 [641]
Almut G Winterstein, Tobias Gerhard. (United States)

168 Prescription of Fixed Combinations of Inhaled Glucocorticosteroid and Long-Acting b2-Agonists for Childhood Asthma in Denmark: Are Guidelines Followed? [642]
Hans K Madsen, Claudia Ranneries, Hans Bisgaard. (Denmark)

169 Alternative Strategies for Diagnosis and Treatment of Pediatric Acute Otitis Media [643]
Sharon B Meropol, Henry A Glick, David A Asch. (United States)

170 Demographic Discrepancies in Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) and Initiation of Pharmacological Treatment in Children and Adolescents: A Study of Florida Medicaid Beneficiaries 1994-2004 [644]
Almut G Winterstein, Tobias Gerhard. (United States)

171 Trends in Off-Label and Unlicensed Prescribing of Psychotropic Drugs to Children in Primary Care (2001-2004) [645]
Anita C Volkers, Liset van Dijk. (Netherlands)

172 A Double-Blind, Placebo-Controlled Study of Olanzapine in Adolescents with Schizophrenia [646]
Ludmila Kryzhanovskaya, Charles Schulz, Christopher J McDougle, Jean A Frazier, Ralf W Dittmann, Carol Robertson-Plouch, Theresa Bauer, Wen Xu, Wei V Wang, Janice Carlson, Mauricio Tohen. (United States)

173 Primary Insomnia in Pediatrics [647]
Laura E Burleson. (United States)

174 Olanzapine in the Treatment of Acute Mania in Adolescents with Bipolar I Disorder; a 3-Week Randomized Double-Blind Placebo-Controlled Study [648]
Mauricio Tohen, Ludmila Kryzhanovskaya, Gabrielle Carlson, Melissa DeBello, Janet Wozniak, Robert Kowatch, Karen Wagner, Robert Findling, Daniel Lin, Carol Robertson-Plouch, Wen Xu, Ralf Dittmann, Joe Biederman. (United States)